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Abstract
Some individuals remain HIV-1 antibody and PCR negative after repeated exposures to the
virus, and are referred to as HIV-exposed seronegatives (HESN). However, the causes of re-
sistance to HIV-1 infection in cases other than those with a homozygous CCR5Δ32 deletion
are unclear. We hypothesized that human p21WAF1/CIP1 (a cyclin-dependent kinase inhibitor)
could play a role in resistance to HIV-1 infection in HESN, as p21 expression has been asso-
ciated with suppression of HIV-1 in elite controllers and reported to block HIV-1 integration in
cell culture.Wemeasured p21 RNA expression in PBMC from 40HESN and 40 low exposure
HIV-1 seroconverters (LESC) prior to their infection using a real-time PCR assay. Comparing
the 20 HESNwith the highest exposure risk (median = 111 partners/2.5 years prior to the 20
LESCwith the lowest exposure risk (median = 1 partner/2.5 years prior), p21 expression
trended higher in HESN in only one of two experiments (P = 0.11 vs. P = 0.80). Additionally,
comparison of p21 expression in the top 40 HESN (median = 73 partners/year) and lowest
40 LESC (median = 2 partners/year) showed no difference between the groups (P = 0.84).
There was a weak linear trend between risk of infection after exposure and increasing p21
gene expression (R2 = 0.02, P = 0.12), but again only in one experiment. Hence, if p21 ex-
pression contributes to the resistance to viral infection in HESN, it likely plays a minor role ev-
ident only in those with extremely high levels of exposure to HIV-1.
Introduction
It is now well established that some persons who have been exposed to HIV-1 repeatedly, or
who exhibit behaviors associated with a high risk of infection, can remain uninfected [1,2,3,4].
These individuals have been referred to as HIV-exposed seronegatives (HESN) [1], and
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represent a uniquely valuable group for identifying potential host factors and/or immune cor-
relates of resistance to HIV infection.
To date, the only host genetic factor consistently found to be associated with protection
from HIV infection is a homozygous 32 base pair deletion in the CCR5 gene, which encodes a
major viral coreceptor [5,6,7]. It has been suggested that variations in beta chemokine ligands
can result in blockade or sequestering of CCR5 and thereby also affect the relative risk or pro-
tection from infection with HIV [8,9]. Reports based on gene expression knockdown studies
have suggested that several other factors, alone or in combination, may contribute to protection
from HIV infection [10,11,12]. Additional candidates suggested to affect host susceptibility to
HIV-1 infection include TRIM5α [13,14], specific KIR-HLA associations [15], APOBEC3G
[16,17], TAP2 Ala665 [18], IRF1 [19], DC-SIGN [20], and TLR9 [21].
p21 is a well-known cyclin-dependent kinase inhibitor (CKI) that can lead to cell cycle ar-
rest upon DNA damage [22,23,24], particularly of activated/memory T cells in mouse studies
[25]. p21 has also been found to be a potent inhibitor of HIV-1 DNA integration, and to be re-
sponsible for resistance to HIV-1 infection in primitive hematopoietic cells [26], activated
CD4+ T cells and monocyte-derived macrophages [27,28]. Moreover, high levels of expression
of p21 have been reported to lower HIV production levels in cell culture [29]. However, others
have found that although p21 expression was higher in CD4+ T cells from HIV controllers
than from healthy controls, it did not correlate with CD4+ T-cell susceptibility to HIV-1 infec-
tion [30].
Based primarily on the data demonstrating suppression of viral integration and resistance
to cellular infection [26,28], we reasoned that individuals with high p21 levels may exhibit re-
sistance to HIV-1 infection. To test this hypothesis, we studied p21 RNA expression levels in
HIV seronegative individuals with risk behaviors suggestive of unusually high levels of HIV ex-
posure, and used as a comparison group HIV-uninfected individuals with reported low risk be-
havior but who nonetheless subsequently acquired HIV-1 infection.
Methods
Study group and ethics statement
The institutional review boards of MACS participating institutions (University of Pittsburgh;
Johns Hopkins University; University of California, Los Angeles; Northwestern University) ap-
proved the MACS study protocol, and written informed consent was obtained from all partici-
pants. The Multicenter AIDS Cohort (MACS), a longitudinal prospective cohort study of HIV
infection in the United States, enrolled 6973 men between the years 1984–2003 [31]. The
MACS collects plasma and peripheral blood mononuclear cells, and clinical data, from HIV-
infected and HIV-uninfected study participants at six-month intervals. The MACS defined a
quantitative estimate of HIV exposure risk, the partner score (pscore), determined by the num-
ber of self-reported different sexual partners and the proportion of those partners with whom
the individual had unprotected anal-receptive intercourse in the 2.5 years before MACS semi-
annual visit 2 (which took place in 1985) [32].
For the current study, we identified HESN and low exposure HIV-1 seroconverters (LESC)
by ranking individuals by pscore. Our initial group of HESN included 20 individuals with the
highest pscores and who remained seronegative for>15 years, studying only individuals of Eu-
ropean descent (for matching purposes in this case-control study) and those that did not pos-
sess any CCR5Δ32 alleles. The initial group of LESC contained 20 HIV-infected individuals
with the lowest pscores, and only individuals of European descent without CCR5Δ32 alleles. All
samples from LESC were obtained 3–9 months prior to HIV-1 infection, as estimated from the
dates of the last HIV antibody seronegative and first seropositive visit. Subsequently, the next
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20 top ranked samples from HESN and LESC (also only individuals of European descent and
with no CCR5Δ32 alleles) were tested (resulting in 40 HESN and 40 LESC). Absolute counts of
circulating CD4+ and CD8+ T cells were available for all subjects. The sample selection proce-
dure employed did not rule out the possibility that some LESC may have been viral RNA+ but
seronegative at the visit evaluated. However, transcriptome analysis of cellular RNA in the top
ranked 20 HESN and LESC failed to reveal HIV infection (data not shown).
RNA extraction and cDNA synthesis
Total RNA was extracted from cryopreserved PBMC using the QIAamp RNA Blood Mini Kit
(Qiagen, USA) and further purified with the TURBO DNA-Free Kit (Ambion, USA) to remove
residual genomic DNA. Purified RNA was then amplified with primers specific to the reference
gene ODC1 (forward: 5’-TGGTAATGAAGAGTTTGACTGCCACTT-3’; reverse: 5’CACTGA-
GACGACAGACTGCTTTGGAA-3’) without prior reverse transcription to confirm the com-
plete removal of genomic DNA; 10 ng genomic DNA was used as a positive control. RNA was
then reverse transcribed with a CDKN1A gene specific primer (5’- AGTGCCAGGAAAGA-
CAACTACT-3’) at a final concentration of 100 nM, and SuperScript III Reverse Transcriptase
(Invitrogen, USA) according to the manufacturer’s protocol.
Real time PCR
This assay was performed in triplicate in 25 ul reaction volumes composed of: 1X Gene Expres-
sion Master Mix (Applied Biosystems, USA), 1X CDKN1A TaqMan Gene Expression Assay
reagents (Applied Biosystems, Hs00355782_m1) and 2.5 ng cDNA. Water and human geno-
mic DNA (500 ng) were used as negative controls (the latter since the probe spans the exon
2/exon 3 junction of the spliced RNA). Reactions were heated to 50°C for 2 minutes, 95°C for
10 minutes, and then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The sequence of
the CDKN1A clone (Open BioSystems, Image 3355833) was verified and used to construct a
standard curve ranging from 3 (lower limit of quantification for the assay) to 3x105 copies.
p21 cDNA copy numbers were determined from amplification plots using ABI7500 software
v2.0.1 (Applied Biosystems, USA).
Statistical analysis
Differences in CD4, CD8, CD4:CD8 ratio, and p21 expression data between HESN and LESC
groups were tested for statistical significance with the Mann-Whitney U test.
Results
Risk levels for HIV infection of HESN and LESC assessed by the
number of reported unprotected sex partners
The 20 individuals with the greatest risk exposure (highest pscore; highest number of individual
sex partners) in the 2.5 years before MACS visit 2 (1984–5) had 80–401 partners during that
time period (median = 111), with the next 20 highest risk individuals having between 50–66
partners (median = 53). Twenty individuals that went on to seroconvert within 1 year, but with
the least risk exposure, had between 0–2 partners (median = 1), while the next group of 20 had
between 2–6 partners (median = 3). Taken together, the top 40 HESN had a median of 73 part-
ners, while the top 40 LESC had a median of 2 partners in the 2.5 years prior to sampling.
We found weak trends between HESN status and lower CD4+ T-cell counts (Mann-
Whitney U test, P = 0.13; HESN median = 899 cells/uL; LESC median = 1116) (S1 Fig.) and
CD8+ T-cell counts (Mann-Whitney U test, P = 0.13; HESN median = 570 cells/uL; LESC
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median = 700) when comparing the top 20 ranked HESN and LESC, but no significant linear
correlation between these values and risk of exposure (S2 Fig.). Furthermore, CD4:CD8 ratios
(Mann-Whitney U test, P = 0.84; HESN median = 1.48; LESC median = 1.31) and CD4 per-
centages were not significantly different between the risk groups (P = 0.86) (S1 Fig.).
No consistently observed differences between p21 expression in very
high risk HESN and very low risk LESC
We conducted 3 experiments to evaluate p21 RNA expression; within each experiment all sam-
ples were evaluated in triplicate. In the first experiment, we observed a trend for higher median
p21 RNA levels in the top 20 ranked HESN compared to the top ranked 20 LESC (Fig. 1A)
(Mann-Whitney U test, P = 0.11). Median levels of expression in HESN were 2,734 copies/ng
cDNA (range 151 to 178,700) compared to 2,024 in LESC (range 162 to 4,196). However, in a
second experiment using the same RNA preparation, no difference was observed between the
2 groups (P = 0.80) (S3 Fig.).
Given the possible trend toward higher p21 RNA expression in the most extreme HESN rel-
ative to the most extreme LESC, we assessed more individuals, i.e., the 20 HESN with the next
highest exposure risks and the 20 LESC with the next lowest exposure risks. This analysis
found no significant difference between the two groups of 40 individuals in p21 RNA expres-
sion (Mann-Whitney U test, P = 0.84) (Fig. 1B). The median level of expression for the top
40 ranked HESN was 1,607 copies/ng cDNA (range 92 to 178,700) compared to 1,779 in LESC
(range 162 to 27,130). A repeat of this experiment again showed no difference between the two
groups of 40 (P = 0.47) (S3 Fig.). Despite the contrasting statistical inferences from the first two
experiments, overall, the p21 copy numbers had very high concordance between the initial and
replicate experiments (R2 = 0.90, P = 2x10-16 for all 80 p21 measurements across both risk
groups) (S4 Fig.).
To determine whether there was a relationship between p21 expression and pscore consid-
ered as a continuous variable, p21 expression levels from the top 40 ranking HESN and the top
40 ranking LESC were compared against individual pscores with uncorrected ordinary least
squares regression. There were essentially flat and non-significant linear relationships between
log10-transformed p21 expression and pscore at the individual level, for both the initial and
replicate experiments (R2 = 0.015, P = 0.29, R2 = 0.004, P = 0.59, respectively) (Fig. 2A). Regres-
sion analysis of only the top 20 ranking HESN and top 20 ranking LESC also showed no signifi-
cant relationship, for both the initial and replicate experiments (R2 = 0.02, P = 0.45, R2 = 0.01,
P = 0.66, respectively) (Fig. 2B).
Discussion
HIV-1 infection is an inefficient and complex process that can be influenced by many factors,
including the route and magnitude of virus exposure as well as innate host factors, only one of
which, the Δ32 mutation in the HIV co-receptor CCR5, has been consistently identified as af-
fecting risk of infection in vivo [5]. Critical examination of extreme risk groups, as described
here, is needed to determine additional host correlates of HIV-1 infection. The results of the
present study suggest that p21 levels play little if any role in protection from HIV infection, de-
spite some prior data indicating that high levels of p21 expression is associated with HIV con-
troller status [30], resistance of HIV target cells to infection in cell culture [26,28] and lower
HIV expression in cell culture [29]. However, the limitations of the current study should be
noted: it had relatively small sample sizes and no direct measurement of HIV exposure, and
unfractionated PBMC were evaluated; it is possible that p21 expression may be different in
pure CD4+ T cell or activated CD4+ T cell populations, where it would be expected to have the
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Fig 1. p21 expression in HESN and LESC. Shown are comparisons of p21 expression between: A) the top 20 ranking HIV-uninfected individuals with the
greatest risk exposure (HESN) and the top 20 ranking HIV-infected individuals with the lowest risk exposure (LESC) (sampled prior to HIV infection); and
B) the top 40 ranking HESN and LESC. All individuals were of European ancestry and none possessed a CCR5Δ32 deletion. p21 count refers to the number
of p21 transcripts per ng of cDNA derived from total PBMC RNA.
doi:10.1371/journal.pone.0119218.g001
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Fig 2. Linear regression comparisons of p21 expression in HESN and LESC. A) Linear regression of log10-transformed p21 count (number of p21
transcripts per ng of cDNA derived from total PBMCRNA) on individual pscores (the partner score, determined by the number of self-reported different
sexual partners and the proportion of those partners with whom the individual had unprotected anal-receptive intercourse in the previous 2.5 years) for the
top 20 ranking HESN and LESC. Shown are initial (black) and replicate (red) experiments. All individuals were of Caucasian ancestry and none possessed
the CCR5Δ32 deletion. B) Plot of linear regression of p21 expression data on individual pscores for the top 40 ranking HESN and LESC, with initial (black)
and replicate (red) experiments shown.
doi:10.1371/journal.pone.0119218.g002
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greatest impact on HIV-1 infection. We could not test this possibility because of limited cell
availability. Thus, although p21 is a hypothetically strong candidate, and perhaps a minor con-
tributor, to natural protection from HIV-1 infection in HESN, a broader search is required to
identify additional major host factors responsible for this protection.
Supporting Information
S1 Fig. Distributions of CD4+ T cell counts in HESN and LESC. Shown are comparisons of
CD4 cells/uL (panel A) and CD4:CD8 ratio (panel B) between the top 20 ranking seronegative
individuals with the greatest risk exposure (HESN) and the top 20 ranking HIV-infected indi-
viduals with the lowest risk exposure (LESC) (sampled prior to HIV infection).
(TIF)
S2 Fig. Linear regression of CD4+ T cell counts versus pscore.No significant linear correla-
tion between CD4+ T cells/uL values and risk of exposure for the top 20 ranked HESN and
LESC.
(TIF)
S3 Fig. Distributions of p21 expression in HESN and LESC from replicate experiments.
Shown here are comparisons of p21 expression, produced from a replicate experiment, be-
tween: A) the top 20 ranking seronegative individuals with the greatest risk exposure (HESN)
and the top 20 ranking seroconverting individuals with the lowest risk exposure (LESC); and
B) the top 40 ranking HESN and LESC.
(TIF)
S4 Fig. Comparison of p21 expression levels estimated in a replicate experiment. Shown
here are comparisons of p21 expression produced from the initial and the replicate experi-
ments for all the top 40 ranking HESN and LESC (for a comparison of 80 p21 measurements
in total).
(TIF)
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